Clinical trials
Phase 2 Immune System Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 13 |
| Completed | 12 |
| Active, not recruiting | 11 |
| Recruiting | 11 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| Center for International Blood and Marrow Transplant Research | 2 |
| Cogent Biosciences, Inc. | 2 |
| Forte Biosciences, Inc. | 2 |
| GlaxoSmithKline | 2 |
| Inmagene LLC | 2 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
| Seagen Inc. | 2 |
| miRagen Therapeutics, Inc. | 2 |
| Alpine Immune Sciences Inc, A Subsidiary of Vertex | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immune System Diseases | 49 |
| Autoimmune Diseases | 17 |
| Lymphoproliferative Disorders | 11 |
| Neoplasms | 10 |
| Immunoproliferative Disorders | 9 |
| Skin Diseases | 9 |
| Lymphatic Diseases | 8 |
| Lymphoma | 8 |
| Dermatitis | 7 |
| Dermatitis, Atopic | 7 |
Trials
Showing 1 to 25 of 49. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.